Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Polypid Ltd.
Industry Sector: HealthTechnology
CEO: Dikla Czaczkes Akselbrad, MBA, CPA
Number Of Employees: 61
Enterprise Value: $11,783,186
PE Ratio: -0.59
Exchange/Ticker 1: NASDAQ:PYPD
Exchange/Ticker 2: N/A
Latest Market Cap: $29,961,200
BioCentury | Jan 3, 2022
Management Tracks
Robertson becomes Opthea’s first CCO
Plus: 4D Pharma, NeuShen, Mind, PolyPid and Biosion
BioCentury | Mar 17, 2021
Finance
European IPOs look to U.S. markets: Data Byte
2020’s top European biotech IPOs listed on NASDAQ, NYSE
BioCentury | Jun 26, 2020
Finance
Akouos’ first-day pop outshines peers among NASDAQ IPO trio
Fusion, PolyPid join the gene therapy company on NASDAQ, Hyloris prices IPO on Euronext
BioCentury | Jun 26, 2020
Finance
Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts
BioCentury | Jun 24, 2020
Finance
June 23 Quick Takes: Illumina selects first biotechs for U.K. accelerator; plus updates from the NASDAQ IPO queue, and venture rounds for Surrozen, Tara
BioCentury | Jun 9, 2020
Finance
Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings
BioCentury | Sep 4, 2019
Financial News
Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more
Items per page:
1 - 10 of 22